Thus, trastuzumab is included with chemotherapy or antiestrogens in the first-line therapy and, commonly, is re-incorporated later with other agents: ado-trastuzumab emtansine (KADCYLA) for the adjuvant treatment of patients with HER-2 positive early breast cancer (EBC) who have the residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment (KATHERINE trial) [26] or lapatinib-containing regimens [27], in patients with HER-2 positive MBC [28]. Here, ERBB2 is linked to breast cancer.